tiprankstipranks
Antares Pharma (ATRS)
NASDAQ:ATRS

Antares Pharma Stock Analysis & Ratings

ATRS Stock Chart & Stats

Day’s Range$5.57 - $5.58
52-Week Range$3.11 - $5.59
Previous Close$5.58
Volume1.35M
Average Volume (3M)3.47M
Market Cap$953.36M
P/E Ratio24.2
Beta1.15
Next EarningsAug 09, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6
EPS (TTM)0.23


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ATRS FAQ

What was Antares Pharma’s price range in the past 12 months?
Antares Pharma lowest stock price was $3.11 and its highest was $5.59 in the past 12 months.
    What is Antares Pharma’s market cap?
    Antares Pharma’s market cap is $953.36M.
      What is Antares Pharma’s price target?
      The average price target for Antares Pharma is $5.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $5.60 ,the lowest forecast is $5.60. The average price target represents 0.36% Increase from the current price of $5.58.
        What do analysts say about Antares Pharma?
        Antares Pharma’s analyst rating consensus is a ‘Hold. This is based on the ratings of 5 Wall Streets Analysts.
          When is Antares Pharma’s upcoming earnings report date?
          Antares Pharma’s upcoming earnings report date is Aug 09, 2022 which is in 82 days.
            How were Antares Pharma’s earnings last quarter?
            Antares Pharma released its earnings results on May 10, 2022. The company reported -$0.014 earnings per share for the quarter, missing the consensus estimate of $0.003 by -$0.017.
              Is Antares Pharma overvalued?
              According to Wall Street analysts Antares Pharma’s price is currently Undervalued.
                Does Antares Pharma pay dividends?
                Antares Pharma does not currently pay dividends.
                What is Antares Pharma’s EPS estimate?
                Antares Pharma’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Antares Pharma have?
                Antares Pharma has 170,850,000 shares outstanding.
                  What happened to Antares Pharma’s price movement after its last earnings report?
                  Antares Pharma reported an EPS of -$0.014 in its last earnings report, missing expectations of $0.003. Following the earnings report the stock price went same 0%.
                    Which hedge fund is a major shareholder of Antares Pharma?
                    Among the largest hedge funds holding Antares Pharma’s share is Oracle Investment Management Inc. It holds Antares Pharma’s shares valued at 7M.

                      ---

                      Antares Pharma Stock Analysis

                      Smart Score
                      6
                      Neutral
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $5.60
                      ▲(0.36% Upside)
                      Hold
                      The Antares Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Antares Pharma

                      Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its proprietary products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Teva Pharmaceutical
                      West Pharmaceutical Services
                      ANI Pharmaceuticals
                      Cardinal Health
                      Eli Lilly & Co

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis